X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.accesswire.com/843636/protagonist-therapeutics-announces-closing-of-worldwide-rusfertide-license-and-collaboration-agreement-with-takeda
https://www.fiercebiotech.com/biotech/twist-protagonist-story-fda-seeks-rescind-breakthrough-nod-based-observed-malignancies
https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-positive-phase-2a-data-supporting-the-potential-use-of-rusfertide-as-a-first-in-class-therapy-in-hereditary-hemochromatosis-301423690.html
https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-updated-data-from-phase-2-study-of-rusfertide-in-polycythemia-vera-selected-for-oral-presentations-at-the-ash-2021-annual-meeting-301416327.html
https://endpts.com/in-quick-turnaround-fda-lifts-full-clinical-hold-on-protagonists-blood-cancer-program/
https://www.evaluate.com/vantage/articles/news/snippets/eyes-return-prize-protagonists-rusfertide
https://www.clinicaltrialsarena.com/news/fda-protagonist-rusfertide-studies/
Market Place
Share 
